Literature DB >> 8848738

The cervical spine in rheumatoid arthritis: relationship between neurologic signs and morphology of MR imaging and radiographs.

M Reijnierse1, J L Bloem, B A Dijkmans, H M Kroon, H C Holscher, B Hansen, F C Breedveld.   

Abstract

OBJECTIVE: Comparison of clinically observed neurologic long tract signs in a heterogeneous group of patients with rheumatoid arthritis (RA), with morphologic abnormalities of the cervical spine as depicted on radiographs and magnetic resonance (MR) images.
DESIGN: The patients were prospectively assigned to one of three classes on the basis of their neurologic status. Lateral cervical spine radiographs and sagittal T1-weighted and gradient echo images were performed. The qualitative MR features evaluated were erosion of the dens and atlas, brain stem compression, subarachnoid space encroachment, pannus around the dens, appearance of the fat body caudal to the clivus, and the signal intensity of the pannus. The quantitative imaging parameters were the cervicomedullary angle and the distance of the dens to the line of McRae. PATIENTS: Sixty-three consecutive patients with RA and subjective symptoms, especially neck or occipital pain, and/or clinical objective signs consistent with a compromised cervical cord were included in this study. RESULTS AND
CONCLUSIONS: Damage documented with radiographs and MR imaging in patients with RA is often severe, even in those without neurologic signs (class 1). None of the abnormalities confined to the atlantoaxial level correlated significantly with neurologic classification. Subarachnoid space encroachment anywhere in the entire cervical spine did correlate significantly with neurologic classification.

Entities:  

Mesh:

Year:  1996        PMID: 8848738     DOI: 10.1007/s002560050046

Source DB:  PubMed          Journal:  Skeletal Radiol        ISSN: 0364-2348            Impact factor:   2.199


  7 in total

1.  Improved medical and surgical management of cervical spine disease in patients with rheumatoid arthritis over 10 years.

Authors:  J D Hamilton; M M Gordon; I B McInnes; R A Johnston; R Madhok; H A Capell
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

2.  Intraspinal pannus formation at C6 in a patient with rheumatoid arthritis causing severe cervical cord compression. A case report.

Authors:  K Shiratori; H D Mennel; S Bien
Journal:  Rheumatol Int       Date:  2003-02-21       Impact factor: 2.631

3.  Interobserver and intraobserver reliability of the cervicomedullary angle in a normal adult population.

Authors:  Shenglin Wang; Chao Wang; Peter G Passias; Gang Li; Ming Yan; Haitao Zhou
Journal:  Eur Spine J       Date:  2009-08-04       Impact factor: 3.134

4.  A retrospective study of congenital osseous anomalies at the craniocervical junction treated by occipitocervical plate-rod systems.

Authors:  Xianjun Ding; Kuniyoshi Abumi; Manabu Ito; Hideki Sudo; Masahiko Takahata; Ken Nagahama; Akira Iwata
Journal:  Eur Spine J       Date:  2012-05-01       Impact factor: 3.134

5.  MRI of the transverse and alar ligaments in rheumatoid arthritis: feasibility and relations to atlantoaxial subluxation and disease activity.

Authors:  Nils Vetti; Rikke Alsing; Jostein Kråkenes; Jarle Rørvik; Nils Erik Gilhus; Johan Gorgas Brun; Ansgar Espeland
Journal:  Neuroradiology       Date:  2010-03       Impact factor: 2.804

6.  Magnetic resonance imaging of the craniovertebral junction in early rheumatoid arthritis.

Authors:  Marina Carotti; Fausto Salaffi; Marco Di Carlo; Francesco Sessa; Andrea Giovagnoni
Journal:  Skeletal Radiol       Date:  2018-09-11       Impact factor: 2.199

7.  Rationale and design of The Delphi Trial--I(RCT)2: international randomized clinical trial of rheumatoid craniocervical treatment, an intervention-prognostic trial comparing 'early' surgery with conservative treatment [ISRCTN65076841].

Authors:  Jasper F C Wolfs; Wilco C Peul; Maarten Boers; Maurits W van Tulder; Ronald Brand; Hans J C van Houwelingen; Raph T W M Thomeer
Journal:  BMC Musculoskelet Disord       Date:  2006-02-16       Impact factor: 2.362

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.